<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663687</url>
  </required_header>
  <id_info>
    <org_study_id>SHP623-100</org_study_id>
    <nct_id>NCT02663687</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ascending Dose, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intravenous and Subcutaneous Doses of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is looking to gain information about the safety and tolerability of an
      investigational treatment (SHP623) in healthy adult volunteers. This study will also collect
      pharmacokinetic data (how the body absorbs and breaks down the study drug).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Actual">December 5, 2016</completion_date>
  <primary_completion_date type="Actual">December 5, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs)</measure>
    <time_frame>From the start of study treatment up to 28 days after the last dose of the study treatment (up to 56 days)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. An AE was considered to be a TEAE in a specific treatment period of the study if the date and time of onset were after investigational product administration in that period and if it occurred less than equals to (&lt;=) Day 28 and was both not present at the start of that period and was not a chronic condition that was part of the participant's medical history, or it was present at the start of that period or as part of the participant's medical history but the severity or frequency increased during that period &lt;= Day 28. An SAE was defined as any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of SHP623 Occurring at Time of Maximum Observed Concentration During a Dosing Interval (Tmax)</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>Cmax of SHP623 recombinant human C1 esterase inhibitor (rC1 INH) antigen at Tmax was calculated based on observed concentration-versus-time data. Cmax at Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) of SHP623 Sampled During a Dosing Interval</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>Tmax of SHP623 (rC1 INH) antigen was calculated based on observed concentration-versus-time data. Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>t1/2 is the time required for the concentration of the drug to reach half of its original value. t1/2 of SHP623 (rC1 INH) antigen for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC 0-inf) of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>AUC 0-inf is the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC 0-inf of SHP623 (rC1 INH) antigen was calculated from observed concentration-versus-time data. AUC 0-inf of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve From Time Zero to 168 Hours Postdose (AUC 0-168) of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>AUC 0-168 is the area under the concentration curve over the interval from 0 to 168 hours after dosing of SHP623. AUC 0-168 of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. AUC 0-168 of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>AUClast is the area under the curve from the time 0 to the last measurable concentration of SHP623 (rC1 INH), which was calculated from observed concentration-versus-time data. AUClast of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL) for Intravascular (IV) Administration of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>CL is the total body clearance of SHP623 for IV administration. The unit of measurement is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution Associated With the Terminal Slope (Vz) Following Intravenous (IV) Administration of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>Vz is the volume of distribution associated with the terminal slope following IV administration. Vz was calculated for SHP 623 (rC1 INH) antigen from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance for Extravascular Administration (CL/F) of SHP623 for Subcutaneous (SC) Administration</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>CL/F is the total body clearance for extravascular administration of SHP623 for SC administration divided by the fraction of dose absorbed. CL/F of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. The unit of measure is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution Influenced by Fraction of Dose Absorbed (Vz/F) Following Extravascular Administration of SHP623</measure>
    <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
    <description>Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed for subcutaneous (SC) administration. Vz/F of SHP623 (rC1 INH) were calculated from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Treatment 1- 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Subjects will receive placebo for each cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human C1 esterase inhibitor</intervention_name>
    <description>Subjects will receive escalating doses I-IV as both IV and SC injections</description>
    <arm_group_label>Treatment 1- 4</arm_group_label>
    <other_name>SHP623</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP623</intervention_name>
    <description>SHP623</description>
    <arm_group_label>Treatment 1- 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be considered healthy. Healthy status is defined by absence of evidence of any
             active or chronic disease

          2. Male, or non-pregnant, non-lactating female, who agrees to comply with any applicable
             contraceptive requirements of the protocol, or females of non-child-bearing potential.

          3. Body mass index between 18.0 and 30.0 kg/m2 inclusive with a body weight &gt;50 kg (110
             lbs.). This inclusion criterion will be assessed only at the first screening visit.

          4. Hemoglobin â‰¥12.0g/ld.

        Exclusion Criteria:

          1. Have a history of allergic reaction to C1 INH products (e.g. C1 Inhibitor [Human],
             Berinert [C1 Estrace Inhibitor (Human)] and C1 estrace [recombinant]

          2. Known history of alcohol or other substance abuse within the last year.

          3. Donation of blood or blood products within 60 days prior to receiving investigational
             product.

          4. Current use of any medication except hormonal replacement therapy, hormonal
             contraceptives and occasional use of any over-the-counter non-steroidal
             anti-inflammatory drug (NSAID) or acetaminophen.

          5. Have a history of hypercoagulability or other predisposition to thrombotic events.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Finkelman, DDS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <results_first_submitted>December 4, 2017</results_first_submitted>
  <results_first_submitted_qc>September 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2018</results_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at a single center in the United States between 19 February 2016 (first participant first visit) and 05 December 2016 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 48 participants were screened, randomized and received at least one dose of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo matched to SHP623 intravenous (IV) and subcutaneous (SC) administration in 1:3 ratio for each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="P2">
          <title>1000 U SHP623</title>
          <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an subcutaneous SC dose.</description>
        </group>
        <group group_id="P3">
          <title>2000 U SHP623</title>
          <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an subcutaneous SC dose.</description>
        </group>
        <group group_id="P4">
          <title>3000 U SHP623</title>
          <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an subcutaneous SC dose.</description>
        </group>
        <group group_id="P5">
          <title>5000 U SHP623</title>
          <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an subcutaneous SC dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Period 1 (IV)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Period 2 (SC)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set consisted of all participants who were administered at least 1 dose of investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo matched to SHP623 intravenous and subcutaneous administration in 1:3 ratio for each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between intravenous (IV) and subcutaneous (SC) dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="B2">
          <title>1000 U SHP623</title>
          <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="B3">
          <title>2000 U SHP623</title>
          <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="B4">
          <title>3000 U SHP623</title>
          <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="B5">
          <title>5000 U SHP623</title>
          <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age was calculated as the difference between date of birth and date of informed consent, truncated to years.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="7.93"/>
                    <measurement group_id="B2" value="40.7" spread="7.25"/>
                    <measurement group_id="B3" value="36.8" spread="7.08"/>
                    <measurement group_id="B4" value="38.0" spread="10.49"/>
                    <measurement group_id="B5" value="35.7" spread="8.63"/>
                    <measurement group_id="B6" value="37.4" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. An AE was considered to be a TEAE in a specific treatment period of the study if the date and time of onset were after investigational product administration in that period and if it occurred less than equals to (&lt;=) Day 28 and was both not present at the start of that period and was not a chronic condition that was part of the participant's medical history, or it was present at the start of that period or as part of the participant's medical history but the severity or frequency increased during that period &lt;= Day 28. An SAE was defined as any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose.</description>
        <time_frame>From the start of study treatment up to 28 days after the last dose of the study treatment (up to 56 days)</time_frame>
        <population>Safety analysis set consisted of all participants who were administered at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to SHP623 intravenous (IV) and subcutaneous (SC) administration in 1:3 ratio for each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O5">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. An AE was considered to be a TEAE in a specific treatment period of the study if the date and time of onset were after investigational product administration in that period and if it occurred less than equals to (&lt;=) Day 28 and was both not present at the start of that period and was not a chronic condition that was part of the participant's medical history, or it was present at the start of that period or as part of the participant's medical history but the severity or frequency increased during that period &lt;= Day 28. An SAE was defined as any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose.</description>
          <population>Safety analysis set consisted of all participants who were administered at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of SHP623 Occurring at Time of Maximum Observed Concentration During a Dosing Interval (Tmax)</title>
        <description>Cmax of SHP623 recombinant human C1 esterase inhibitor (rC1 INH) antigen at Tmax was calculated based on observed concentration-versus-time data. Cmax at Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of SHP623 Occurring at Time of Maximum Observed Concentration During a Dosing Interval (Tmax)</title>
          <description>Cmax of SHP623 recombinant human C1 esterase inhibitor (rC1 INH) antigen at Tmax was calculated based on observed concentration-versus-time data. Cmax at Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
          <population>Pharmacokinetic (PK) set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>microgram per milliliter (mcg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intravenous (IV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.911" spread="14.5979"/>
                    <measurement group_id="O2" value="130.367" spread="31.3581"/>
                    <measurement group_id="O3" value="160.556" spread="22.1083"/>
                    <measurement group_id="O4" value="307.000" spread="54.6374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous (SC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.248" spread="1.7445"/>
                    <measurement group_id="O2" value="15.694" spread="4.2062"/>
                    <measurement group_id="O3" value="16.318" spread="4.5612"/>
                    <measurement group_id="O4" value="32.056" spread="8.7727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Plasma Concentration (Tmax) of SHP623 Sampled During a Dosing Interval</title>
        <description>Tmax of SHP623 (rC1 INH) antigen was calculated based on observed concentration-versus-time data. Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax) of SHP623 Sampled During a Dosing Interval</title>
          <description>Tmax of SHP623 (rC1 INH) antigen was calculated based on observed concentration-versus-time data. Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intravenous (IV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.25" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.250" lower_limit="0.25" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.25" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.500" lower_limit="0.25" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous (SC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.000" lower_limit="36.00" upper_limit="144.00"/>
                    <measurement group_id="O2" value="36.000" lower_limit="24.00" upper_limit="72.00"/>
                    <measurement group_id="O3" value="48.000" lower_limit="36.00" upper_limit="96.00"/>
                    <measurement group_id="O4" value="48.000" lower_limit="36.00" upper_limit="96.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2) of SHP623</title>
        <description>t1/2 is the time required for the concentration of the drug to reach half of its original value. t1/2 of SHP623 (rC1 INH) antigen for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of SHP623</title>
          <description>t1/2 is the time required for the concentration of the drug to reach half of its original value. t1/2 of SHP623 (rC1 INH) antigen for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intravenous (IV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="24.6" upper_limit="38.6"/>
                    <measurement group_id="O2" value="40.2" lower_limit="30.2" upper_limit="45.8"/>
                    <measurement group_id="O3" value="38.2" lower_limit="33.6" upper_limit="48.2"/>
                    <measurement group_id="O4" value="38.9" lower_limit="31.7" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous (SC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="34.0" upper_limit="80.4"/>
                    <measurement group_id="O2" value="49.8" lower_limit="42.4" upper_limit="65.9"/>
                    <measurement group_id="O3" value="59.5" lower_limit="46.3" upper_limit="71.7"/>
                    <measurement group_id="O4" value="51.8" lower_limit="35.8" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC 0-inf) of SHP623</title>
        <description>AUC 0-inf is the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC 0-inf of SHP623 (rC1 INH) antigen was calculated from observed concentration-versus-time data. AUC 0-inf of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC 0-inf) of SHP623</title>
          <description>AUC 0-inf is the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC 0-inf of SHP623 (rC1 INH) antigen was calculated from observed concentration-versus-time data. AUC 0-inf of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>hr*mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intravenous (IV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1114.535" spread="368.6962"/>
                    <measurement group_id="O2" value="2941.364" spread="348.6029"/>
                    <measurement group_id="O3" value="4278.273" spread="663.0496"/>
                    <measurement group_id="O4" value="8282.120" spread="1118.0116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous (SC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594.741" spread="101.0006"/>
                    <measurement group_id="O2" value="1653.875" spread="318.0261"/>
                    <measurement group_id="O3" value="2304.409" spread="590.0275"/>
                    <measurement group_id="O4" value="4174.091" spread="854.5110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve From Time Zero to 168 Hours Postdose (AUC 0-168) of SHP623</title>
        <description>AUC 0-168 is the area under the concentration curve over the interval from 0 to 168 hours after dosing of SHP623. AUC 0-168 of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. AUC 0-168 of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve From Time Zero to 168 Hours Postdose (AUC 0-168) of SHP623</title>
          <description>AUC 0-168 is the area under the concentration curve over the interval from 0 to 168 hours after dosing of SHP623. AUC 0-168 of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. AUC 0-168 of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>hr*mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intravenous (IV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1069.451" spread="365.0676"/>
                    <measurement group_id="O2" value="2823.169" spread="311.8634"/>
                    <measurement group_id="O3" value="4083.493" spread="623.9060"/>
                    <measurement group_id="O4" value="7893.069" spread="1010.5182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous (SC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.936" spread="149.3221"/>
                    <measurement group_id="O2" value="1414.762" spread="328.9591"/>
                    <measurement group_id="O3" value="1792.962" spread="488.0679"/>
                    <measurement group_id="O4" value="3386.375" spread="790.1633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of SHP623</title>
        <description>AUClast is the area under the curve from the time 0 to the last measurable concentration of SHP623 (rC1 INH), which was calculated from observed concentration-versus-time data. AUClast of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of SHP623</title>
          <description>AUClast is the area under the curve from the time 0 to the last measurable concentration of SHP623 (rC1 INH), which was calculated from observed concentration-versus-time data. AUClast of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>hr*mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intravenous (IV)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1054.798" spread="369.5553"/>
                    <measurement group_id="O2" value="2868.736" spread="344.7756"/>
                    <measurement group_id="O3" value="4174.135" spread="664.8862"/>
                    <measurement group_id="O4" value="8168.337" spread="1127.0107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous (SC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.030" spread="147.1284"/>
                    <measurement group_id="O2" value="1518.124" spread="341.5602"/>
                    <measurement group_id="O3" value="2159.527" spread="599.1840"/>
                    <measurement group_id="O4" value="4040.772" spread="845.6065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance (CL) for Intravascular (IV) Administration of SHP623</title>
        <description>CL is the total body clearance of SHP623 for IV administration. The unit of measurement is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL) for Intravascular (IV) Administration of SHP623</title>
          <description>CL is the total body clearance of SHP623 for IV administration. The unit of measurement is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>U/(hr*mcg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.961" spread="0.2229"/>
                    <measurement group_id="O2" value="0.688" spread="0.0802"/>
                    <measurement group_id="O3" value="0.718" spread="0.1233"/>
                    <measurement group_id="O4" value="0.614" spread="0.0857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution Associated With the Terminal Slope (Vz) Following Intravenous (IV) Administration of SHP623</title>
        <description>Vz is the volume of distribution associated with the terminal slope following IV administration. Vz was calculated for SHP 623 (rC1 INH) antigen from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution Associated With the Terminal Slope (Vz) Following Intravenous (IV) Administration of SHP623</title>
          <description>Vz is the volume of distribution associated with the terminal slope following IV administration. Vz was calculated for SHP 623 (rC1 INH) antigen from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>U/(mcg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.600" spread="10.7552"/>
                    <measurement group_id="O2" value="37.284" spread="4.8077"/>
                    <measurement group_id="O3" value="40.794" spread="6.9950"/>
                    <measurement group_id="O4" value="35.684" spread="4.6175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance for Extravascular Administration (CL/F) of SHP623 for Subcutaneous (SC) Administration</title>
        <description>CL/F is the total body clearance for extravascular administration of SHP623 for SC administration divided by the fraction of dose absorbed. CL/F of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. The unit of measure is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment oeriod 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance for Extravascular Administration (CL/F) of SHP623 for Subcutaneous (SC) Administration</title>
          <description>CL/F is the total body clearance for extravascular administration of SHP623 for SC administration divided by the fraction of dose absorbed. CL/F of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. The unit of measure is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>U/(hr*mcg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.723" spread="0.2965"/>
                    <measurement group_id="O2" value="1.250" spread="0.2445"/>
                    <measurement group_id="O3" value="1.399" spread="0.4512"/>
                    <measurement group_id="O4" value="1.254" spread="0.3199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution Influenced by Fraction of Dose Absorbed (Vz/F) Following Extravascular Administration of SHP623</title>
        <description>Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed for subcutaneous (SC) administration. Vz/F of SHP623 (rC1 INH) were calculated from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].</description>
        <time_frame>Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.</time_frame>
        <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>1000 U SHP623</title>
            <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O2">
            <title>2000 U SHP623</title>
            <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O3">
            <title>3000 U SHP623</title>
            <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
          <group group_id="O4">
            <title>5000 U SHP623</title>
            <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution Influenced by Fraction of Dose Absorbed (Vz/F) Following Extravascular Administration of SHP623</title>
          <description>Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed for subcutaneous (SC) administration. Vz/F of SHP623 (rC1 INH) were calculated from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].</description>
          <population>PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.</population>
          <units>U/(mcg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.585" spread="48.5385"/>
                    <measurement group_id="O2" value="94.861" spread="27.1022"/>
                    <measurement group_id="O3" value="121.511" spread="37.3158"/>
                    <measurement group_id="O4" value="94.463" spread="30.0244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of study treatment up to 28 days after the last dose of the study treatment (up to 56 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo matched to SHP623 intravenous (IV) and subcutaneous (SC) administration in 1:3 ratio for each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="E2">
          <title>1000 U SHP623</title>
          <description>Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="E3">
          <title>2000 U SHP623</title>
          <description>Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="E4">
          <title>3000 U SHP623</title>
          <description>Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
        <group group_id="E5">
          <title>5000 U SHP623</title>
          <description>Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonmentor termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

